Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-76

“The children continued to show clinical and laboratory improvements and were well- appearing by day of discharge (MUSC hospital day 9 and 10, respectively). Both children continue to be followed as outpatients and are doing well (to date, both are ≥90 days out from first remestemcel-L dose). Importantly, both children tolerated remestemcel-L well with no adverse effects, consistent with remestemcel-L ‘a previously reported favourable safety profile in children.24
Although both children were showing some level of clinical improvement when they received the experimental product, the data suggest that remestemcel-L contributed to further improvements in myocardial and endothelial function and promoted additional reductions in systemic and cardiac inflammation. Within one day of his first remestemcel-L treatment, patient #1’s D-dimer levels decreased from levels that were above the measurable range to values that were rapidly approaching normal. The most likely mechanisms of action that facilitated these improvements include multi-targeted, beneficial anti-inflammatory effects that promote endothelial function and protect cardiomyocytes from apoptosis and fibrosis.“